4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 53 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,218,405 | -32.1% | 1,902,467 | -3.6% | 0.00% | 0.0% |
| Q2 2023 | $35,653,952 | +34.2% | 1,973,102 | +27.6% | 0.00% | 0.0% |
| Q1 2023 | $26,573,745 | -6.0% | 1,545,884 | +21.5% | 0.00% | 0.0% |
| Q4 2022 | $28,255,785 | +166.1% | 1,272,210 | -3.6% | 0.00% | – |
| Q3 2022 | $10,617,000 | +15.1% | 1,320,362 | -0.1% | 0.00% | – |
| Q2 2022 | $9,228,000 | -52.7% | 1,322,149 | +2.4% | 0.00% | – |
| Q1 2022 | $19,519,000 | -30.7% | 1,290,941 | +0.6% | 0.00% | -100.0% |
| Q4 2021 | $28,152,000 | +10.3% | 1,283,083 | +35.6% | 0.00% | 0.0% |
| Q3 2021 | $25,513,000 | +125.3% | 945,977 | +101.2% | 0.00% | – |
| Q2 2021 | $11,325,000 | -40.3% | 470,276 | +7.6% | 0.00% | -100.0% |
| Q1 2021 | $18,969,000 | +4481.9% | 437,262 | +4272.6% | 0.00% | – |
| Q4 2020 | $414,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |